CVA Family Office’s Rhythm Pharmaceuticals RYTM Stock Holding History

CVA Family Office’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33K	Sell	12 -16	-57%	-$1.45K	﹤0.01%	1592
2026 Q1	$2.44K	Buy	28 +16	+133%	+$1.56K	﹤0.01%	1466
2025 Q4	$1.28K	Hold	12	–	–	﹤0.01%	1060
2025 Q3	$1.21K	Hold	12	–	–	﹤0.01%	1097
2025 Q2	$758	Hold	12	–	–	﹤0.01%	1140
2025 Q1	$636	Hold	12	–	–	﹤0.01%	1180
2024 Q4	$672	Hold	12	–	–	﹤0.01%	1161
2024 Q3	$629	Hold	12	–	–	﹤0.01%	1148
2024 Q2	$493	Buy	+12	New	+$479	﹤0.01%	1218

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CVA Family Office's RYTM Position: Q2 2026 in Review

CVA Family Office reduced its Rhythm Pharmaceuticals (RYTM) stake by 57% in Q2 2026, selling an estimated $1.45K and leaving 12 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

CVA Family Office first reported a position in RYTM in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.44K in Q1 2026. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

CVA Family Office held 12 shares of Rhythm Pharmaceuticals worth $1.33K as of Q2 2026.
CVA Family Office sold 16 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.45K.
Rhythm Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1592 holding.
CVA Family Office first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
CVA Family Office's Rhythm Pharmaceuticals position peaked at $2.44K in Q1 2026.
305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.